• 1
    Kyle RA, Lust JA. Monoclonal gammopathies of undetermined significance. Semin Hematol. 1989; 26: 176200.
  • 2
    Kyle RA. “Benign” monoclonal gammopathy after 20 to 35 years of follow-up. Mayo Clin Proc. 1993; 68: 2636.
  • 3
    Blade J, Lopez-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol. 1992; 81: 391394.
  • 4
    Kyle RA, Beard CM, O'Fallon WM, Kurland LT. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Clin Oncol. 1994; 12: 15771583.
  • 5
    Durie BG. Cellular and molecular genetic features of myeloma and related disorders. Hematol Oncol Clin North Am. 1992; 6: 463477.
  • 6
    Kyle RA. Why better prognostic factors for multiple myeloma are needed. Blood. 1994; 83: 17131716.
  • 7
    Tabernero MD, San Miguel JF, Garcia-Sanz M, et al. Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol. 1996; 149: 153161.
  • 8
    Pérez-Simon JA, García-Sanz R, Tabernero MD, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood. 1998; 91: 33663371.
  • 9
    Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 1995; 55: 38543859.
  • 10
    Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001; 97: 822825.
  • 11
    García-Sanz R, Orfao A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999; 93: 10321037.
  • 12
    Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood. 1995; 86: 39153921.
  • 13
    Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol. 1995; 90: 693696.
  • 14
    Zandecki M, Lai JL, Genevieve F, et al. Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. Blood. 1997; 90: 36823690.
  • 15
    Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999; 59: 45464550.
  • 16
    Avet-Loiseau H, Brigaudeau C, Morineau N, et al. High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1999; 24: 915.
  • 17
    Konigsberg R, Ackermann J, Kaufmann H, et al. Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia. 2000; 14: 19751979.
  • 18
    Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998; 101: 711.
  • 19
    Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001; 98: 22662268.
  • 20
    Fonseca R, Ahmann GJ, Jalal SM, et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 1998; 103: 704710.
  • 21
    Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep. 1973; 4: 145158.
  • 22
    Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974; 133: 813818.
  • 23
    Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998; 152: 16551665.
  • 24
    San Miguel JF, Almeida J, Mateo G, et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002; 99: 18531856.
  • 25
    Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer. 1997; 18: 8493.
  • 26
    Lee W, Han K, Drut RM, Harris CP, Meisner LF. Use of fluorescence in situ hybridization for retrospective detection of aneuploidy in multiple myeloma. Genes Chromosomes Cancer. 1993; 7: 137143.
  • 27
    Flactif M, Zandecki M, Lai JL, et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995; 9: 21092114.
  • 28
    Avet-Loiseau H, Li JY, Morineau N, et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. Blood. 1999; 94: 25832589.
  • 29
    Ackermann J, Meidlinger P, Zojer N, et al. Absence of p53 deletions in bone marrow plasma cells of patients with monoclonal gammopathy of undetermined significance. Br J Haematol. 1998; 103: 11611163.
  • 30
    Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995; 86: 42504256.
  • 31
    Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000; 95: 19251930.
  • 32
    Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000; 96: 15051511.
  • 33
    Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998; 92: 802809.
  • 34
    Durie BGM. Annotation: is myeloma really a monoclonal disease? Br J Haematol. 1984; 57: 357363.
  • 35
    Leonard RCF, MacLennan ICM, Smart Y, Vanhegan RI, Cuzick J. Light-chain isotype-associated suppression of normal plasma cell numbers in patients with multiple myeloma. Int J Cancer. 1979; 24: 385393.
  • 36
    Nicholls M, Vincent PC, Repka E, Saunders J, Gunz FW. Isotypic discordance of paraproteins and lymphocyte surface immunoglobulins in myeloma. Blood. 1981; 57: 192195.
  • 37
    Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of biclonal gammopathies. Review of 57 cases. Am J Med. 1981; 71: 9991008.
  • 38
    Adlersberg JB, Grann V, Zucker-Franklin D, Frangione B, Franklin EC. An unusual case of a plasma cell neoplasma with an IgG3λ myeloma and a γ3 heavy chain disease protein. Blood. 1978; 51: 8595.
  • 39
    Ockhuizen T, Steen G, Muilerman HG, et al. A biclonal origin of two monoclonal proteins, IgG3(K) and IgA1(λ), from a single patient. Immunology. 1979; 37: 863868.
  • 40
    Dworsky E, Sletten K, Harboe M, Wetteland P. Structural studies of three IgGK proteins from a patient with multiple myeloma. Scand J Immunol. 1980; 12: 281287.
  • 41
    Bartoloni C, Flamini G, Gentiloni N, et al. Immunochemical and ultrastructural study of multiple myeloma with a heavy chain protein in the serum. J Clin Pathol. 1980; 33: 936945.
  • 42
    Scolari L, Vaerman JP, Castigli D, et al. Late appearance of an IgA(k) monoclonal protein in a patient with IgG(k) multiple myeloma: sharing of idiotypic: specificities between the two serum proteins. Scand J Immunol. 1978; 8: 201206.
  • 43
    Carter A, Spira G, Manaster J, Tatarsky I. Spontaneous immunoglobulin changes in human plasma-cell dyscrasia. Scand J Immunol. 1981; 27: 111118.
  • 44
    Weitzman S, Margulies DH, Scharff MD. Mutations in mouse myeloma cells: implications for human multiple myeloma and the production of immunoglobulins. Ann Intern Med. 1976; 85: 110116.
  • 45
    Durie BGM, Vela E, Baum V, et al. Establishment of two new myeloma cell lines from bilateral pleural effusions: evidence for sequential in vivo clonal change. Blood. 1985; 66: 548555.